David Loew, Ipsen CEO (Ipsen via Twitter)
February 11, 2022 11:00 AM EST
Pharma

Hunt­ing more R&D deals, Ipsen is ham­mer­ing out a $460M sale of con­sumer ops while cut­ting costs

John Carroll

Editor & Founder

These days, con­sumer health di­vi­sions rep­re­sent a con­ve­nient source of cash as phar­ma play­ers dou­ble down on their R&D op­er­a­tions and hunt new deals. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump’s sci­ence crack­down hits rare dis­ease re­search: ‘We need to sit down with Elon Musk’

At least sev­en drug­mak­ers say they will par­tic­i­pate in round two of IRA ne­go­ti­a­tions 

Lil­ly joins mol­e­c­u­lar glue field with Mag­net deal worth up to $1.25B

Ex­clu­sive: In­fec­tious dis­ease doc­tors con­sid­er 'mi­ni-ACIP' if RFK erodes CDC vac­cine pan­el

Bridge­Bio on­col­o­gy spin­out to go pub­lic via com­bi­na­tion with SPAC from Cor­morant and Bi­hua Chen

sponsored

How AI can ad­dress on­go­ing chal­lenges in the life sci­ences in­dus­try

A service from the Financial Times